Syros Pharmaceuticals Plans to Wind Down Operations

Dow Jones

02-28

Syros Pharmaceuticals Inc.-11.26%盤後

By Josh Beckerman

Syros Pharmaceuticals said it plans to wind down its operations, according to a Securities and Exchange Commission filing.

The Cambridge, Mass., company said it would proceed with a voluntary delisting from Nasdaq.

Syros shares last traded at 14 cents, down 0.8%. The stock was halted due to pending news.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

By Josh Beckerman

Syros Pharmaceuticals, which said in November it would cut most of its workforce, said on Friday it will wind down operations.

The company's stock dropped 45% to 8 cents in after-hours trading. Through the market's close shares have plunged 98% in the last year.

Syros is voluntarily delisting its stock from Nasdaq.

The company said in November that it planned to reduce its workforce by about 94% after a Phase 3 study of tamibarotene failed to meet its primary endpoint.

The failure constituted an event of default under its secured loan facility with Oxford Finance LLC. Syros said that it agreed to operate its business as a wind-down and limit its expenditures in accordance with a budget approved by Oxford.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

February 28, 2025 17:27 ET (22:27 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

no data

沒有相關數據

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2516212307"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516212307\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2516212307?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-01 05:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516212307","market":"other","top_or_hot":-1,"title":"Syros Pharmaceuticals Plans to Wind Down Operations","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Syros Pharmaceuticals said it plans to wind down its operations, according to a Securities and Exchange Commission filing. \n</p>\n<p>\n  The Cambridge, Mass., company said it would proceed with a voluntary delisting from Nasdaq. \n</p>\n<p>\n  Syros shares last traded at 14 cents, down 0.8%. The stock was halted due to pending news. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n</font><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Josh Beckerman \n</p>\n<p>\n  Syros Pharmaceuticals, which said in November it would cut most of its workforce, said on Friday it will wind down operations. \n</p>\n<p>\n  The company's stock dropped 45% to 8 cents in after-hours trading. Through the market's close shares have plunged 98% in the last year. \n</p>\n<p>\n  Syros is voluntarily delisting its stock from Nasdaq. \n</p>\n<p>\n  The company said in November that it planned to reduce its workforce by about 94% after a Phase 3 study of tamibarotene failed to meet its primary endpoint. \n</p>\n<p>\n  The failure constituted an event of default under its secured loan facility with Oxford Finance LLC. Syros said that it agreed to operate its business as a wind-down and limit its expenditures in accordance with a budget approved by Oxford. \n</p>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 28, 2025 17:27 ET (22:27 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Syros Pharmaceuticals Plans to Wind Down Operations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSyros Pharmaceuticals Plans to Wind Down Operations\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-03-01 05:41</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Syros Pharmaceuticals said it plans to wind down its operations, according to a Securities and Exchange Commission filing. \n</p>\n<p>\n  The Cambridge, Mass., company said it would proceed with a voluntary delisting from Nasdaq. \n</p>\n<p>\n  Syros shares last traded at 14 cents, down 0.8%. The stock was halted due to pending news. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n</font><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Josh Beckerman \n</p>\n<p>\n  Syros Pharmaceuticals, which said in November it would cut most of its workforce, said on Friday it will wind down operations. \n</p>\n<p>\n  The company's stock dropped 45% to 8 cents in after-hours trading. Through the market's close shares have plunged 98% in the last year. \n</p>\n<p>\n  Syros is voluntarily delisting its stock from Nasdaq. \n</p>\n<p>\n  The company said in November that it planned to reduce its workforce by about 94% after a Phase 3 study of tamibarotene failed to meet its primary endpoint. \n</p>\n<p>\n  The failure constituted an event of default under its secured loan facility with Oxford Finance LLC. Syros said that it agreed to operate its business as a wind-down and limit its expenditures in accordance with a budget approved by Oxford. \n</p>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 28, 2025 17:27 ET (22:27 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SYRS","symbol_name":"Syros Pharmaceuticals Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2516212307","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516212307","pubTimestamp":1740778860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Syros Pharmaceuticals said it plans to wind down its operations, according to a Securities and Exchange Commission filing.The Cambridge, Mass., company said it would proceed with a voluntary delisting from Nasdaq.Syros shares last traded at 14 cents, down 0.8%. The stock was halted due to pending news.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SYRS":"Syros Pharmaceuticals Inc.","BK4139":"生物科技"},"translate_title":"Syros制药公司计划缩减业务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYRS":1},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Syros Pharmaceuticals said it plans to wind down its operations, according to a Securities and Exchange Commission filing. \n\n\n  The Cambridge, Mass., company said it would proceed with a voluntary delisting from Nasdaq. \n\n\n  Syros shares last traded at 14 cents, down 0.8%. The stock was halted due to pending news. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n\n  By Josh Beckerman \n\n\n  Syros Pharmaceuticals, which said in November it would cut most of its workforce, said on Friday it will wind down operations. \n\n\n  The company's stock dropped 45% to 8 cents in after-hours trading. Through the market's close shares have plunged 98% in the last year. \n\n\n  Syros is voluntarily delisting its stock from Nasdaq. \n\n\n  The company said in November that it planned to reduce its workforce by about 94% after a Phase 3 study of tamibarotene failed to meet its primary endpoint. \n\n\n  The failure constituted an event of default under its secured loan facility with Oxford Finance LLC. Syros said that it agreed to operate its business as a wind-down and limit its expenditures in accordance with a budget approved by Oxford. \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 17:27 ET (22:27 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}

如果下載按鈕點擊無跳轉，請點擊右上角菜單選擇 “在瀏覽器打開”

立即諮詢
下載APP
掃碼下載APP